Literature DB >> 11101010

Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats.

P O Jensen1, B T Mortensen, R J Hodgkiss, P O Iversen, I J Christensen, N Helledie, J K Larsen.   

Abstract

The microenvironmental changes in the bone marrow, spleen and liver during progression of the transplantable promyelocytic leukaemia in the Brown Norwegian rat (BNML) have been studied. We used flow cytometry to estimate cellular hypoxia and proliferation based on in vivo pulse-labelling with a mixture of 2-nitroimidazole linked to theophylline (NITP) and bromodeoxyuridine (BrdUrd). The leukaemic cells were identified with the RM124 antibody. In rats inoculated with leukaemic cells the fraction of RM124+ cells was significantly increased from day 20 onwards in the spleen and from day 27 in the bone marrow and liver, reaching a level of 65-87% in these organs at day 32. At day 32, the NITP+ fraction of RM124+ cells had increased significantly in the bone marrow and spleen to 88% and 90%, respectively. The corresponding fractions of NITP+ normal cells reached 63% and 65%, respectively. From day 13 to day 32, the DNA-synthesizing (BrdUrd+) fraction of RM124+ cells in the bone marrow decreased significantly from 52% to 25%, and of normal cells from about 20% to 6%. In the bone marrow and spleen at day 27 and 32, the S-phase and G2/M-phase fractions according to DNA content were higher for the NITP+ than for the NITP- cells. This could partly be explained by an impaired cell cycle progression due to hypoxia. Nevertheless, we found indications of leukaemic cells that were simultaneously labelled with NITP and BrdUrd, in the bone marrow and spleen. These latter findings suggest that in contrast to normal cells some of the leukaemic cells can proliferate even during hypoxia, and this subpopulation may consequently renew and expand the leukaemic cell load.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11101010      PMCID: PMC6496496          DOI: 10.1046/j.1365-2184.2000.00183.x

Source DB:  PubMed          Journal:  Cell Prolif        ISSN: 0960-7722            Impact factor:   6.831


  18 in total

1.  The in vitro sensitivities to radiation and misonidazole of mouse bone marrow cells derived from different microenvironments.

Authors:  J Allalunis-Turner; J D Chapman
Journal:  Int J Radiat Biol Relat Stud Phys Chem Med       Date:  1986-03

2.  Characteristics of a monoclonal antibody (RM124) against acute myelocytic leukemia cells.

Authors:  A C Martens; R J Johnson; H Kaizer; A Hagenbeek
Journal:  Exp Hematol       Date:  1984-09       Impact factor: 3.084

3.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma.

Authors:  D M Brizel; S P Scully; J M Harrelson; L J Layfield; J M Bean; L R Prosnitz; M W Dewhirst
Journal:  Cancer Res       Date:  1996-03-01       Impact factor: 12.701

4.  Decreased blood flow to rat bone marrow, bone, spleen, and liver in acute leukemia.

Authors:  P O Iversen; B Thing-Mortensen; G Nicolaysen; H B Benestad
Journal:  Leuk Res       Date:  1993-08       Impact factor: 3.156

5.  Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats.

Authors:  B T Mortensen; P O Jensen; N Helledie; P O Iversen; E Ralfkiaer; J K Larsen; M T Madsen
Journal:  Br J Haematol       Date:  1998-07       Impact factor: 6.998

6.  Blood flow to bone marrow during development of anemia or polycythemia in the rat.

Authors:  P O Iversen; G Nicolaysen; H B Benestad
Journal:  Blood       Date:  1992-02-01       Impact factor: 22.113

7.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours.

Authors:  T G Graeber; C Osmanian; T Jacks; D E Housman; C J Koch; S W Lowe; A J Giaccia
Journal:  Nature       Date:  1996-01-04       Impact factor: 49.962

8.  Simultaneous triple staining for hypoxia, proliferation, and DNA content in murine tumours.

Authors:  L Webster; R J Hodgkiss; G D Wilson
Journal:  Cytometry       Date:  1995-12-01

9.  Inadequate vasculature in solid tumours: consequences for cancer research strategies.

Authors:  J Denekamp
Journal:  BJR Suppl       Date:  1992

10.  Flow cytometric evaluation of hypoxic cells in solid experimental tumours using fluorescence immunodetection.

Authors:  R J Hodgkiss; G Jones; A Long; J Parrick; K A Smith; M R Stratford; G D Wilson
Journal:  Br J Cancer       Date:  1991-01       Impact factor: 7.640

View more
  27 in total

Review 1.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

2.  Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.

Authors:  Talha Badar; Damian R Handisides; Juliana M Benito; Mary Ann Richie; Gautam Borthakur; Elias Jabbour; Karine Harutyunyan; Sergej Konoplev; Stefan Faderl; Stew Kroll; Michael Andreeff; Tillman Pearce; Hagop M Kantarjian; Jorge E Cortes; Deborah A Thomas; Marina Konopleva
Journal:  Am J Hematol       Date:  2016-06-25       Impact factor: 10.047

Review 3.  Advances in understanding the leukaemia microenvironment.

Authors:  Yoko Tabe; Marina Konopleva
Journal:  Br J Haematol       Date:  2014-01-09       Impact factor: 6.998

Review 4.  Development and maintenance of cancer stem cells under chronic inflammation.

Authors:  Toshihiko Tanno; William Matsui
Journal:  J Nippon Med Sch       Date:  2011       Impact factor: 0.920

Review 5.  Targeting the microenvironment in acute myeloid leukemia.

Authors:  Armin Rashidi; Geoffrey L Uy
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

Review 6.  Leukemia stem cells and microenvironment: biology and therapeutic targeting.

Authors:  Marina Y Konopleva; Craig T Jordan
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

7.  Hypoxia favors chemoresistance in T-ALL through an HIF1α-mediated mTORC1 inhibition loop.

Authors:  Lucine Fahy; Julien Calvo; Sara Chabi; Laurent Renou; Charly Le Maout; Sandrine Poglio; Thierry Leblanc; Arnaud Petit; André Baruchel; Paola Ballerini; Irina Naguibneva; Rima Haddad; Marie-Laure Arcangeli; Frederic Mazurier; Francoise Pflumio; Benjamin Uzan
Journal:  Blood Adv       Date:  2021-01-26

8.  Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment.

Authors:  Linhua Jin; Yoko Tabe; Hongbo Lu; Gautam Borthakur; Takashi Miida; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Lett       Date:  2012-10-02       Impact factor: 8.679

9.  Targeting hypoxia in the leukemia microenvironment.

Authors:  Juliana Benito; Zhihong Zeng; Marina Konopleva; William R Wilson
Journal:  Int J Hematol Oncol       Date:  2013-08-01

10.  Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine.

Authors:  Giulia Cheloni; Michele Tanturli; Ignazia Tusa; Ngoc Ho DeSouza; Yi Shan; Antonella Gozzini; Fréderic Mazurier; Elisabetta Rovida; Shaoguang Li; Persio Dello Sbarba
Journal:  Blood       Date:  2017-06-02       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.